Background Adverse drug reactions (ADRs) monitoring in cancer patients is important to ensure early detection, effective management and possible prevention subsequently. Objectives This study was conducted to detect and monitor ADRs to anti-cancer agents, and to assess impact of clinical pharmacists (CPs)’ interventions in minimizing ADRs to anti-cancer agents. Setting Private, specialty oncology care hospital in South India. Methods CPs prospectively followed cancer patients admitted to inpatient wards and treated at ambulatory care in order to identify ADRs, for a period of 3 years. Identified/reported ADRs were discussed with concerned oncologists and/or nurses, documented electronically and assessed further for their causality, severity, preventability and grading. Based on study findings during year 1, interventions (educational, therapeutic and system based) were developed by CPs and implemented in order to minimize preventable ADRs. Impact of CPs’ interventions was studied during year 2 and year 3. Main outcome measure(s) Preventable factors contributing to ADRs and percentage of preventable ADRs before and after CPs’ interventions. Results A total of 1279 ADRs were reported in 1133 patients from a cohort of 1328 patients. Vomiting (23.22%), alopecia (9.53%), diarrhoea (8.67%) and myelosuppression (7.42%) were the common ADRs reported. Inappropriate administration frequency and regimen of anti-emetics (22%), lack of/suboptimal supportive care (18%) and administration errors (16%) were identified as common contributing (preventable) factors for ADRs in year 1. Percentage of preventable ADRs was 81% during year 1 (pre-intervention), and 45% and 34% in year 2 and year 3 respectively (post-interventions). Conclusion Interventions by CPs helped to minimize preventable ADRs to anti-cancer agents.
Adverse drug reactions Anti-cancer agents Clinical pharmacists India Oncology care
This is a preview of subscription content, log in to check access.
Authors thank physicians and nurses of JSS Academy of Higher Education and Research collaborated oncology practice site and, JSS Academy of Higher Education and Research, Mysore, India for their support and encouragement. We thank Ms Karin Nyfort-Hansen, Clinical Pharmacist, South Australia for her comments on the earlier version of this manuscript.
No funding was received for this study from any source.
Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341–67.CrossRefPubMedGoogle Scholar
Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol. 1997;53(1):19–22.CrossRefPubMedGoogle Scholar
Kukec RR, Grabnar I, Vovk T, Mrhar A, Kovac V, Cufer T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol Oncol. 2015;49(2):173–80.CrossRefPubMedPubMedCentralGoogle Scholar
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. Drug Saf. 2016;39(9):859–72.CrossRefPubMedGoogle Scholar
Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42.CrossRefPubMedPubMedCentralGoogle Scholar
Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016;8:83.CrossRefPubMedPubMedCentralGoogle Scholar
Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–5.CrossRefPubMedGoogle Scholar
Caracuel F, Banos U, Herrera MD, Ramirez G, Munoz N. Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm. 2014;36:287–90.CrossRefPubMedGoogle Scholar
Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm. 2010;67(7 Suppl 3):S20–30.CrossRefPubMedGoogle Scholar
Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. In: Mayo clinic proceedings, vol. 87, no. 10. Elsevier; 2012. p. 935–43.Google Scholar
Sharma A, Kumari KM, Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res. 2015;6(2):109.CrossRefPubMedPubMedCentralGoogle Scholar
Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83–94.CrossRefPubMedGoogle Scholar
US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. 2009.Google Scholar
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMedPubMedCentralGoogle Scholar
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49(9):2229–32.CrossRefGoogle Scholar
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.PubMedGoogle Scholar
Patel H, Gurumurthy P. Implementation of clinical pharmacy services in an academic oncology practice in India. J Oncol Pharm Pract. 2017;1:1078155217739684.Google Scholar
Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41(2):199–205.CrossRefPubMedGoogle Scholar
Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143–50.CrossRefPubMedGoogle Scholar
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–43.CrossRefPubMedGoogle Scholar
LeBaron VT, Palat G, Sinha S, Chinta SK, Jamima BJ, Pilla UL, et al. Recommendations to support nurses and improve the delivery of oncology and palliative care in India. Indian J Palliat Care. 2017;23(2):188–98.CrossRefPubMedPubMedCentralGoogle Scholar
Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, et al. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. Asian Pac J Cancer Prev. 2015;16:1699–705.CrossRefPubMedGoogle Scholar
Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci. 2015;77(6):687.CrossRefPubMedPubMedCentralGoogle Scholar
Vijayalaxmi MK, Palatty PL, Bhat P, Dinesh M. A comparative assessment of the ADR profile in various anti-cancer regimens excluding gastro-intestinal and haematological toxicity at a tertiary care centre. J Clin Diagn Res. 2011;5:1209–13.Google Scholar
Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12(9):626–33.PubMedGoogle Scholar
Sano HS, Waddell JA, Solimando DA Jr, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract. 2005;1:21–30.CrossRefGoogle Scholar